全文获取类型
收费全文 | 4125篇 |
免费 | 214篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 60篇 |
儿科学 | 146篇 |
妇产科学 | 124篇 |
基础医学 | 548篇 |
口腔科学 | 60篇 |
临床医学 | 249篇 |
内科学 | 1162篇 |
皮肤病学 | 114篇 |
神经病学 | 323篇 |
特种医学 | 137篇 |
外科学 | 477篇 |
综合类 | 20篇 |
一般理论 | 3篇 |
预防医学 | 373篇 |
眼科学 | 95篇 |
药学 | 246篇 |
中国医学 | 8篇 |
肿瘤学 | 205篇 |
出版年
2023年 | 22篇 |
2021年 | 57篇 |
2020年 | 43篇 |
2019年 | 46篇 |
2018年 | 89篇 |
2017年 | 54篇 |
2016年 | 71篇 |
2015年 | 95篇 |
2014年 | 79篇 |
2013年 | 126篇 |
2012年 | 316篇 |
2011年 | 338篇 |
2010年 | 119篇 |
2009年 | 99篇 |
2008年 | 271篇 |
2007年 | 271篇 |
2006年 | 287篇 |
2005年 | 280篇 |
2004年 | 290篇 |
2003年 | 267篇 |
2002年 | 242篇 |
2001年 | 194篇 |
2000年 | 232篇 |
1999年 | 129篇 |
1998年 | 23篇 |
1997年 | 15篇 |
1996年 | 10篇 |
1995年 | 9篇 |
1993年 | 5篇 |
1992年 | 15篇 |
1991年 | 14篇 |
1990年 | 22篇 |
1989年 | 16篇 |
1988年 | 15篇 |
1987年 | 15篇 |
1986年 | 20篇 |
1985年 | 13篇 |
1984年 | 7篇 |
1983年 | 7篇 |
1982年 | 5篇 |
1979年 | 10篇 |
1978年 | 8篇 |
1977年 | 8篇 |
1975年 | 6篇 |
1974年 | 6篇 |
1973年 | 7篇 |
1972年 | 8篇 |
1971年 | 8篇 |
1969年 | 6篇 |
1968年 | 5篇 |
排序方式: 共有4350条查询结果,搜索用时 15 毫秒
1.
2.
Marie Warrer Petersen Tine Sylvest Meyhoff Marie Helleberg Maj-Brit Nørregaard Kjær Anders Granholm Carl Johan Steensen Hjortsø Thomas Steen Jensen Morten Hylander Møller Peter Buhl Hjortrup Mik Wetterslev Gitte Kingo Vesterlund Lene Russell Vibeke Lind Jørgensen Klaus Tjelle Thomas Benfield Charlotte Suppli Ulrik Anne Sofie Andreasen Thomas Mohr Morten H. Bestle Lone Musaeus Poulsen Mette Friberg Hitz Thomas Hildebrandt Lene Surland Knudsen Anders Møller Christoffer Grant Sølling Anne Craveiro Brøchner Bodil Steen Rasmussen Henrik Nielsen Steffen Christensen Thomas Strøm Maria Cronhjort Rebecka Rubenson Wahlin Stephan Jakob Luca Cioccari Balasubramanian Venkatesh Naomi Hammond Vivekanand Jha Sheila Nainan Myatra Christian Gluud Theis Lange Anders Perner 《Acta anaesthesiologica Scandinavica》2020,64(9):1365-1375
Introduction
Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists.Methods
The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving ≥10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.Discussion
The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.3.
4.
5.
6.
A premature male infant, birth-weight 1460 g, was treated successfully for a Candida albicans septicemia with orally administered fluconazole for 20 days. Dosage was 5 mg/kg/day. No side effects were seen. Fluconazole may present a major progress in treatment of invasive C. albicans infections in neonatology. 相似文献
7.
8.
9.
Blanka Ríhová Jirí Strohalm Jana Prausová Katerina Kubácková Markéta Jelínková Lad'ka Rozprimová Milada Sírová Dana Plocová Tomás Etrych Vladimír Subr Tomás Mrkvan Marek Kovár Karel Ulbrich 《Journal of controlled release》2003,91(1-2):1-16
An N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier containing doxorubicin and human immunoglobulin as an actively/passively targeting moiety was used in four patients with generalized breast cancer resistant to standard cytotoxic chemotherapy. The dose and time schedule were deduced from a Phase I clinical trial in which doxorubicin bound to HPMA copolymer carrier (PK1) was tested. It was confirmed that the Dox-HPMA-HuIg conjugate is stable and doxorubicin remains in the peripheral blood with a small amount also in the urine, mostly in its polymer-bound form. More than 116 biochemical, immunological and hematological parameters were determined for blood samples taken from patients 24 h, 48 h, 72 h and 1 to 11 weeks after treatment. Depending on the patient, some parameters decreased permanently or temporarily to the normal level (CRP, C3, CA 72-4, beta(2)-microglobulin, ferritin, CEA, CA 125, CD4, CD8, CE19, CD16(+)56(+), leu, ery) and some moved markedly towards physiological values (AST, ALT, ALP, GMT, CA 15-3, NSE, AFP). While the number of peripheral blood reticulocytes was significantly decreased after treatment with the classical free drug, their number was not affected or was even elevated after treatment with Dox-HPMA-HuIg. Increased absolute numbers of CD16(+)56(+) and CD4(+) cells in the peripheral blood and activation of NK and LAK cells in all patients support data obtained in experimental animals, pointing to a dual, i.e. cytostatic and immunomobilizing character of Dox-HPMA conjugates containing a targeting immunoglobulin moiety. 相似文献
10.
Effect of simethicone on lactulose-induced H2 production and gastrointestinal symptoms. 总被引:1,自引:0,他引:1
The results of studies of the effect of simethicone on abdominal gas-related symptoms have been contradictory. In a randomized, double-blind cross-over study, 10 healthy volunteers were given 30 g lactulose and 600 mg simethicone or placebo. End-expiratory breath samples were collected and analyzed for H2 and gastrointestinal symptoms registered. There were no differences in biochemical parameters or symptom score between simethicone and placebo. In contrast to previous studies, we used a sufficiently large dose of lactulose to produce gastrointestinal symptoms, a higher dose of simethicone and placebo tablets containing the same additives as the simethicone tablets. There was no demonstrable effect of simethicone on symptoms or intestinal gas production caused by carbohydrate malabsorption. 相似文献